AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10376615 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting‐enzyme (ACE) inhibitor
Number of subjects: 56
Study 10376615 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker
Number of subjects: 56
Study 10376615 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium‐channel blocker
Number of subjects: 56
Study 10376615 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 56
Study 8910814 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (20-30 mmol/l)
Number of subjects: 12
Study 8910814 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemia (5-10 mmol/l)
Number of subjects: 12
Study 1799899 — intervention group
Group type: EXPERIMENTAL
Intervention: NTTS/c (20 mg patch at 8.00 am and at 8.00 pm)
Number of subjects: 18
Study 1799899 — intervention group
Group type: EXPERIMENTAL
Intervention: NTTS/a (20 mg patch at 8.00 am and 10 mg at 8.00 pm)
Number of subjects: 18
Study 1799899 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study 7046702 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoxide dismutase
Number of subjects: 51
Study 7046702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31076187 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg citalopram
Number of subjects: 38
Study 31076187 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 38
Study 29848787 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 75
Study 29848787 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 75
Study 26440810 — intervention group
Group type: EXPERIMENTAL
Intervention: BGStar® blood glucose meter
Number of subjects: 110
Study 26440810 — intervention group
Group type: EXPERIMENTAL
Intervention: FreeStyle Lite® blood glucose meter
Number of subjects: 110
Study 26440810 — intervention group
Group type: COMPARATOR
Intervention: Both meters
Number of subjects: 110
Study 24690329 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐piece resuscitator
Number of subjects: 1027
Study 24690329 — intervention group
Group type: COMPARATOR
Intervention: Self‐inflating bag
Number of subjects: 1027
Study 22206447 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular metal tibial monoblock component (TM)
Number of subjects: 70
Study 22206447 — intervention group
Group type: COMPARATOR
Intervention: Cemented component
Number of subjects: 70
Study 20658837 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-choice paradigm (FCP)
Number of subjects: 0
Study 20658837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical theorem
Number of subjects: 0
Study 17547167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookstoves (planchas) that vent woodsmoke outdoors through a chimney
Number of subjects: 20
Study 17547167 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal exposure measurements determined by carbon monoxide (CO) passive diffusion tubes
Number of subjects: 20
Study 17547167 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitchen area measurements of PM2.5 mass, PM2.5 levoglucosan, and CO
Number of subjects: 20
Study 14763548 — intervention group
Group type: EXPERIMENTAL
Intervention: Graftjacket tissue matrix (single administration)
Number of subjects: 0
Study 14763548 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 12147570 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 1
Study 12147570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 11079739 — intervention group
Group type: EXPERIMENTAL
Intervention: IGT/NFG (2-h glucose 7.8-11.0 mmol/l, fasting glucose < 6.1 mmol/l)
Number of subjects: 265
Study 11079739 — intervention group
Group type: EXPERIMENTAL
Intervention: IFG/NGT (fasting glucose 6.1-6.9 mmol/l, 2-h glucose < 7.8 mmol/l)
Number of subjects: 265
Study 11079739 — intervention group
Group type: EXPERIMENTAL
Intervention: IGT/IFG
Number of subjects: 265
Study 11079739 — intervention group
Group type: COMPARATOR
Intervention: NFG/NGT
Number of subjects: 265
Study 8792507 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests for pyuria and nitrite
Number of subjects: 819
Study 8792507 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli and Staphylococcus saprophyticus
Number of subjects: 819
Study 8792507 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus saprophyticus
Number of subjects: 819
Study 8792507 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 819
Study 1731858 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic and low erucic acid rapeseed oil diet
Number of subjects: 59
Study 1731858 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated sunflower oil diet
Number of subjects: 59
Study 1731858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 59
Study 6375803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (350, 700, and 1400 micrograms)
Number of subjects: 14
Study 6375803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl (1.25, 2.5, and 5 mg)
Number of subjects: 14
Study 6375803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31635689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention plus: bespoke online behaviour change package intervention and personal supplies of moisturising cream for student nurses; optimal availability of moisturising cream for intensive care unit nurses.
Number of subjects: 1956
Study 31635689 — intervention group
Group type: COMPARATOR
Intervention: Intervention light: usual care including a dermatitis prevention leaflet.
Number of subjects: 1956
Study 31635689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention plus for intensive care unit nurses.
Number of subjects: 1956
Study 31635689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention plus for student nurses.
Number of subjects: 1956
Study 30312411 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 223
Study 30312411 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 223
Study 26661906 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1186
Study 26661906 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1186
Study 26661906 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1186
Study 26661906 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/Metformin
Number of subjects: 1186
Study 26661906 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/Metformin
Number of subjects: 1186
Study 26661906 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted ΔHbA1c for canagliflozin/metformin arms
Number of subjects: 1186
Study 26661906 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted ΔHbA1c from new model
Number of subjects: 1186
Study 26661906 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed ΔHbA1c from new model
Number of subjects: 1186
Study 26661906 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted ΔHbA1c assuming additivity
Number of subjects: 1186
Study 24582087 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic model for discriminating UC from HV
Number of subjects: 0
Study 24582087 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic model for discriminating UC from CD
Number of subjects: 0
Study 24582087 — intervention group
Group type: EXPERIMENTAL
Intervention: Model for assessing UC
Number of subjects: 0
Study 21350803 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for advanced gastric cancer
Number of subjects: 10484
Study 19844183 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexposure Prophylaxis to the Infant (PEPI) with breastfeeding cessation by 6 months
Number of subjects: 0
Study 19844183 — intervention group
Group type: COMPARATOR
Intervention: nevirapine/AZT (NVAZ) with prolonged breastfeeding
Number of subjects: 0
Study 17561927 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 125
Study 17561927 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate
Number of subjects: 125
Study 17561927 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice hydrolysate
Number of subjects: 125
Study 17561927 — intervention group
Group type: COMPARATOR
Intervention: Breastfed (non-randomized group)
Number of subjects: 125
Study 15759025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination therapy (CCBs + ARBs)
Number of subjects: 302
Study 15759025 — intervention group
Group type: COMPARATOR
Intervention: High-dose CCBs
Number of subjects: 302
Study 15759025 — intervention group
Group type: COMPARATOR
Intervention: High-dose ARBs
Number of subjects: 302
Study 12409683 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily
Number of subjects: 579
Study 12409683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579
Study 10223241 — intervention group
Group type: EXPERIMENTAL
Intervention: NEO chemoendocrine therapy
Number of subjects: 195
Study 10223241 — intervention group
Group type: COMPARATOR
Intervention: ADJ chemoendocrine therapy
Number of subjects: 195
Study 8830307 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A (2000 U Dysport) alone
Number of subjects: 10
Study 8830307 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (2000 U Dysport) with additional repetitive alternating electrical stimulation
Number of subjects: 10
Study 2195861 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/day)
Number of subjects: 100
Study 2195861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31724703 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM group
Number of subjects: 41
Study 31724703 — intervention group
Group type: COMPARATOR
Intervention: Memory group
Number of subjects: 41
Study 31724703 — intervention group
Group type: COMPARATOR
Intervention: Without AB group
Number of subjects: 41
Study 30949831 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 84
Study 30949831 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group
Number of subjects: 84
Study 25621943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 0.5 mg every 4 weeks
Number of subjects: 46
Study 25621943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks
Number of subjects: 46
Study 25621943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 3 monthly doses (2q8)
Number of subjects: 46
Study 25621943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) as-needed after 3 monthly doses
Number of subjects: 46
Study 25621943 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 46
Study 24101054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg, day 1, 21-day cycle) plus erlotinib (150 mg per day)
Number of subjects: 1145
Study 24101054 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (15 mg/kg, day 1, 21-day cycle) plus placebo
Number of subjects: 1145
Study 22099189 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment (200 IU/kg•d, 3 times weekly for 2 to 4 weeks)
Number of subjects: 70
Study 22099189 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment
Number of subjects: 70
Study 19367047 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation training program (three sessions at four-week intervals) including lectures on responses to stress, coping skills, problem-solving training, group discussions, and self-monitoring.
Number of subjects: 140
Study 19367047 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (no intervention).
Number of subjects: 140
Study 16943453 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley crackers (BCr)
Number of subjects: 10
Study 16943453 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley cookies (Bc)
Number of subjects: 10
Study 16943453 — intervention group
Group type: COMPARATOR
Intervention: Whole-wheat crackers (WWCr)
Number of subjects: 10
Study 16943453 — intervention group
Group type: COMPARATOR
Intervention: Whole-wheat cookies (WWc)
Number of subjects: 10
Study 15313090 — intervention group
Group type: EXPERIMENTAL
Intervention: Special training program using Solutions for Smoking as the main teaching tool
Number of subjects: 15
Study 15313090 — intervention group
Group type: COMPARATOR
Intervention: Standard training program
Number of subjects: 15
Study 11776303 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (prescribed between weeks 15-34)
Number of subjects: 57
Study 11776303 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (s.c. enoxaparin) and low dose aspirin
Number of subjects: 57
Study 11776303 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 57
Study 11776303 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin and low dose aspirin
Number of subjects: 57
Study 9231837 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of intense endurance training
Number of subjects: 10
Study 9231837 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in activity)
Number of subjects: 10
Study 7956572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continent patients
Number of subjects: 17
Study 7956572 — intervention group
Group type: COMPARATOR
Intervention: Incontinent patients
Number of subjects: 17
Study 3300537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Number of subjects: 32
Study 3300537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Number of subjects: 32
Study 3300537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (general recommendation)
Number of subjects: 32
Study 3300537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (urine concentration)
Number of subjects: 32
Study 29322401 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day mirabegron
Number of subjects: 159
Study 27330719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 112
Study 27330719 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study 24239431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-SR 150 mg
Number of subjects: 19
Study 24239431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22025146 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d
Number of subjects: 331
Study 22025146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 20192280 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 40
Study 20192280 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 40
Study 20192280 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 40
Study 20192280 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 40
Study 20192280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18534325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic essential oil massage (1% Zingiber officinale and 0.5% Citrus sinesis)
Number of subjects: 59
Study 18534325 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (olive oil massage)
Number of subjects: 59
Study 18534325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 59
Study 18534325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic essential oil massage
Number of subjects: 59
Study 18534325 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 59
Study 16177470 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (0.8 mg) after mifepristone (200 mg)
Number of subjects: 150
Study 16177470 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (0.8 mg) after mifepristone (200 mg)
Number of subjects: 150
Study 16177470 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued oral misoprostol (0.4 mg twice daily for 7 days)
Number of subjects: 150
Study 12502670 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 27
Study 12502670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 10094948 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg midazolam
Number of subjects: 20
Study 10094948 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 20
Study 10094948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8750486 — intervention group
Group type: EXPERIMENTAL
Intervention: gentamycin plus clindamycin (N = 40)
Number of subjects: 78
Study 8750486 — intervention group
Group type: COMPARATOR
Intervention: ceftazidime plus doxycycline (N = 36)
Number of subjects: 78
Study 1869374 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial incision
Number of subjects: 228
Study 1869374 — intervention group
Group type: COMPARATOR
Intervention: Circumferential incision
Number of subjects: 228
Study 6355050 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acyclovir
Number of subjects: 0
Study 6355050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 0
Study 6355050 — intervention group
Group type: COMPARATOR
Intervention: Steroids
Number of subjects: 0
Study 30883913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair cortisol concentrations (HCC) in participants with PTSD
Number of subjects: 28
Study 30883913 — intervention group
Group type: COMPARATOR
Intervention: Hair cortisol concentrations (HCC) in trauma-exposed controls
Number of subjects: 28
Study 29807962 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% hyaluronic acid gel (GENGIGEL®) applied subgingivally after scaling and root planing (SRP)
Number of subjects: 24
Study 29807962 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no hyaluronic acid gel)
Number of subjects: 24
Study 29807962 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% hyaluronic acid gel (GENGIGEL®)
Number of subjects: 24
Study 27316678 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week anti-inflammatory diet
Number of subjects: 20
Study 27316678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 24704648 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone group (modified chest compression method)
Number of subjects: 64
Study 24704648 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (standardized chest compression method)
Number of subjects: 64
Study 22468861 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 (6 U)
Number of subjects: 323
Study 22468861 — intervention group
Group type: COMPARATOR
Intervention: BHI 30 (6 U)
Number of subjects: 323
Study 22468861 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 323
Study 22468861 — intervention group
Group type: COMPARATOR
Intervention: BHI 30
Number of subjects: 323
Study 20502866 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Ergyphilus, 2 x 10(10) lactic acid bacteria, mostly Lactobacillus rhamnosus GG, once a day)
Number of subjects: 167
Study 20502866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 20502866 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 167
Study 17916258 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/d
Number of subjects: 756
Study 17916258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 756
Study 16005902 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fasudil, intravenous injection over 60 min, twice daily for 14 days
Number of subjects: 160
Study 16005902 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline), intravenous injection over 60 min, twice daily for 14 days
Number of subjects: 160
Study 12435254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose (300 mg) followed by clopidogrel (75 mg/d) for 12 months
Number of subjects: 2116
Study 12435254 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by placebo for 12 months
Number of subjects: 2116
Study 12435254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel loading dose (300 mg) given at least 6 hours before PCI
Number of subjects: 2116
Study 12435254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 2116
Study 10604294 — intervention group
Group type: EXPERIMENTAL
Intervention: High-tension glaucoma
Number of subjects: 46
Study 10604294 — intervention group
Group type: COMPARATOR
Intervention: Normal-tension glaucoma
Number of subjects: 46
Study 7496640 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for major depressive disorder (specific treatments not detailed), lasting 16 weeks.
Number of subjects: 113
Study 1685465 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 800 mg at night (n=8)
Number of subjects: 46
Study 1685465 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg twice daily (n=10)
Number of subjects: 46
Study 1685465 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg at night (n=12)
Number of subjects: 46
Study 1685465 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine 300 mg at night (n=8)
Number of subjects: 46
Study 1685465 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 40 mg at night (n=8)
Number of subjects: 46
Study 1685465 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 46
Study 1685465 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole group after stopping H2 blockade
Number of subjects: 46
Study 6800539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital outpatient care
Number of subjects: 376
Study 6800539 — intervention group
Group type: COMPARATOR
Intervention: General practice care
Number of subjects: 376